Vision
1) Develop novel immune-modifying biologic therapeutics for rare autoimmune diseases with unmet need

2) Target best-fit therapeutic mechanism of action for rare autoimmune disease with applicability in multiple autoimmune indications

3) First advance therapeutic in rare autoimmune disease, then further expand portfolio

new disease mechanistic insights
&
clinically validated biological targets
=
novel, accelerated, de-risked
drug development


Approach
• Begin at validation and drug target product profile design
• Faster to value inflection points (clinical trials)
• De-risked from a target clinical safety perspective
• Novel indication-target pairing with freedom to operate and new intellectual property
• Capital efficiency coupled with non-dilutive funding sources (grant awards)

Team

Jack Lin, Ph.D.
CEO and Co-founder

Nikunj (Nick) Donde, B.S.
Research Associate

Robert Place, Ph.D.
Co-founder

Emily Stein, Ph.D.
Co-founder
























Pipeline
ANV-103 (Uveitis)
Stage: Pre-clinical (lead candidate optimization)
• Non-infectious autoimmune uveitis is a rare inflammatory disease affecting the posterior segments of the eye
ANV-201 (Neuromyelitis Optica)
Stage: Pre-clinical (lead candidate optimization)
• Neuromyelitis Optica (NMO) is a rare neuro-inflammatory disease affecting the spinal cord and optic nerve























News
JAN 12, 2016
Anvil Biosciences will be in attendance at RESI in San Francisco (Jan. 12, 2016)
OCT 18, 2015
Anvil Biosciences will be in attendance at BIO Investor Forum in San Francisco (Oct. 18-19, 2015)
JULY 1, 2014
Anvil Biosciences has been awarded an SBIR grant from NIH - National Institutes of Allergy and Infectious Diseases for a therapeutics development project in neuro-inflammation
MAR. 19, 2014
Dr. Robert Place, Co-founder of Anvil Biosciences, publishes review article on non-coding RNAs: "Non-coding RNAs turn up the heat: an emerging layer of novel regulators in the mammalian heat shock response."
Pubmed
MAR. 1, 2014
Anvil Biosciences has been awarded an SBIR grant from NIH - National Eye Institute for a therapeutics development project in ocular inflammation























Address
Stacks Image 1213
3563 Arden Rd.
Hayward, CA 94545